We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


DSM Biologics and Crucell Announce Licensing Agreement with Medarex

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DSM Biologics and Crucell Announce Licensing Agreement with Medarex"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

DSM Biologics and Dutch biotechnology company Crucell N.V. have announced a PER.C6® license agreement with biopharmaceutical company Medarex, Inc.

This license agreement allows Medarex to use the PER.C6® production platform in its antibody research. Financial details of the agreement were not disclosed.